Stryker Corporation $SYK Shares Sold by Sei Investments Co.

Sei Investments Co. cut its stake in Stryker Corporation (NYSE:SYK) by 55.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 229,287 shares of the medical technology company’s stock after selling 285,503 shares during the period. Sei Investments Co.’s holdings in Stryker were worth $75,347,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Norges Bank acquired a new stake in Stryker in the fourth quarter worth approximately $1,822,272,000. Auto Owners Insurance Co boosted its stake in Stryker by 35,047.0% during the 4th quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock valued at $1,024,444,000 after purchasing an additional 2,906,448 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Stryker by 22.6% during the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after purchasing an additional 1,198,665 shares during the period. Corient Private Wealth LLC increased its position in shares of Stryker by 104.4% during the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after purchasing an additional 1,146,998 shares during the period. Finally, Credit Agricole S A bought a new stake in shares of Stryker in the 3rd quarter worth $194,045,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Price Performance

SYK opened at $330.69 on Friday. The firm has a market capitalization of $126.77 billion, a P/E ratio of 38.27, a PEG ratio of 2.04 and a beta of 0.77. The stock has a fifty day moving average of $314.69 and a 200-day moving average of $335.66. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.14.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities analysts forecast that Stryker Corporation will post 14.99 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is 40.74%.

Insider Buying and Selling at Stryker

In other news, VP M Kathryn Fink sold 3,500 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the transaction, the vice president directly owned 177 shares in the company, valued at $50,170.65. The trade was a 95.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 323,264 shares of company stock valued at $100,659,489 in the last quarter. Company insiders own 4.60% of the company’s stock.

Analysts Set New Price Targets

SYK has been the subject of several research analyst reports. Wall Street Zen lowered Stryker from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Robert W. Baird set a $385.00 target price on Stryker in a report on Friday, May 1st. Weiss Ratings cut shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. Truist Financial restated a “hold” rating and set a $330.00 price objective (down from $380.00) on shares of Stryker in a research report on Monday, May 4th. Finally, Argus set a $370.00 price objective on shares of Stryker in a research note on Thursday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $392.52.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.